

2019 SMR Congress Agenda 11.15 Version			
Wednesday, November 20th	Functions	Speaker	Location
9:00am - 6:00pm	Registration Open		Ballroom Foyer
6:00pm - 7:30pm	Opening Session	Session Chairs: Georgina Long & Sheri Holmen	Grand Ballroom B&C
6:00pm - 6:20pm	Opening Remarks		
6:30pm - 7:30pm	Keynote Presentation: Cellular conversations that control cancer	Thea Tlsty	
7:30pm - 9:00pm	Welcome Reception		Imperial Ballroom A-D
Thursday, November 21st	Functions	Speaker	Location
6:15am - 7:30am	Breakfast		Grand Ballroom Reception/ Imperial Ballroom Reception
6:30am - 5:00pm	Registration Open		Ballroom Foyer
6:45am - 7:45am	Newly-Diagnosed Melanoma – Focus on BRAF-Mutated Disease Provided by Vindico Medical Education Supported by Bristol-Myers Squibb; Iovance Biotherapeutics; and Novartis Pharmaceuticals Corporation		Grand Ballroom B&C
8:00am-10:00am	PLENARY SESSION 1 - RAS Family GTPase Signaling	Session Chair: Jessie Villanueva	Grand Ballroom B&C
8:00am - 8:30am	A new therapeutic strategy for mutant NRAS-driven melanoma	Rutao Cui	
8:30am - 8:45am	BRAF/MEK inhibitors induce potent ER stress-enforced apoptosis in BRAFwt/NRASmut melanoma cells – insights into mode of action and resistance mechanisms	Dana Westphal	
8:45am - 9:00am	Efficient BRAFV600E-driven melanomagenesis requires the trafficking protein ARF6	Allie Grossmann	
9:00am - 9:15am	RAC1P29S induces a mesenchymal phenotypic switch via SRF to promote melanoma development and therapy resistance	Daniël Lionarons	
9:15am - 9:50am	Killer Lamellipodia: How elevated actin polymerization in response to RacP29S activation confers enhanced proliferation in drug-challenged and metastatic melanoma	Gaudenz Danuser	
10:00am - 10:30am	Refreshment Break		Imperial Ballroom A&B
10:30am - 12:30pm	PLENARY SESSION 2- Modeling Melanoma in the Immunotherapy Era	Session Chair: Marcus Bosenberg	Grand Ballroom B&C
10:30am - 11:00am	Modeling melanoma to understand and overcome resistance to signaling and immune therapies	Meenhard Herlyn	
11:00am - 11:30am	Impact of tumor-resident DC populations on anti-tumor T cell responses	Stefani Spranger	
11:30am - 11:45am	Multi-model preclinical platform correlates melanoma multipotency and differentiation status with clinical response to immunotherapy	Eva Perez-Guijarro	
11:45am - 12:15pm	Dying to get noticed: Immunogenic cell death as a component of cancer immunotherapy	Andrew Oberst	
12:30pm - 2:00pm	Lunch - Exhibit and Poster Viewing		Grand Ballroom Reception/ Imperial Ballroom Reception
12:45pm - 1:45pm	Advances in Melanoma Management – Focus on Adjuvant Treatment and Recurring Disease Provided by Vindico Medical Education Supported by Bristol-Myers Squibb; Iovance Biotherapeutics; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation		Grand Ballroom B&C
2:00pm - 3:30pm	PLENARY SESSION 3 - Women in Science	Session Chairs: Alison Betof-Warner, Marie Webster & Jennifer McQuade	Grand Ballroom B&C
2:00pm - 2:30pm	Inspiration and Empowerment for Women in Science: The Huntsman Cancer Institute Experience	Mary Beckerle	
3:30pm - 4:00pm	Refreshment Break		Imperial Ballroom A&B
4:00pm - 5:45pm	CONCURRENT BREAKOUT SESSION 4A - Melanoma Epigenetics	Session Chair: Kenneth Grossmann	Grand Ballroom B&C
4:00pm - 4:30pm	Enhancer reprogramming during resistance to anti-PD1 therapy	Kunal Rai	
4:30pm - 4:45pm	CDK13 mutations drive melanoma via accumulation of prematurely terminated transcripts	Megan Insko	
4:45pm - 5:00pm	BRAF inhibition in melanoma is associated with progressive loss of histone H3 methylation	James Robinson	
5:15pm - 5:30pm	Regulation of 3D genome organization by the STAG2 tumor suppressor in melanoma	Bin Zheng	
5:30pm-5:45pm	MacroH2A as a novel chromatin regulator of the melanoma microenvironment	Dan Filipescu	
4:00pm - 5:45pm	CONCURRENT BREAKOUT SESSION 4B - Advances in Melanoma Predisposition, Early Detection and Prevention	Session Chair: Susan Swetter	Grand Ballroom A&D
4:00pm - 4:30pm	Germline Predisposition in Melanoma: The Devil in the Details	Alexander Lazar	
4:30pm - 5:00pm	Melanoma early detection studies in Australia	Monika Janda	
5:00pm - 5:30pm	Melanoma Early Detection: Oregon's Public Health Experiment	Sancy Leachman	
5:30pm - 5:45pm	Increased frequency of albinism alleles in individuals with amelanotic/hypomelanotic melanoma	Richard Sturm	
5:45pm - 7:00pm	Poster Reception		Imperial Ballroom C&D

Friday, November 22nd	Functions	Speaker	Location
6:15am - 7:30am	Breakfast		Grand Ballroom Reception/ Imperial Ballroom Reception
6:30am - 5:30pm	Registration Open		Ballroom Foyer
6:45am - 7:45am	Checkpoint Inhibitors for Newly-Diagnosed Melanoma – Applying the Latest Advances to Optimize Decision Making Provided by Vindico Medical Education Supported by Bristol-Myers Squibb; Iovance Biotherapeutics; and Novartis Pharmaceuticals Corporation		Grand Ballroom B&C
8:00am - 10:00am	PLENARY SESSION 5 - Melanoma Metastasis: Models and Mechanism	Session Chair: Glenn Merlino	Grand Ballroom B&C
8:00am - 8:30am	<i>Differentiation state determines oncogenic competence in melanoma</i>	Richard White	
8:30am - 8:45am	AKT1E17K activates focal adhesion kinase and promotes melanoma brain metastasis	David Kircher	
8:45am - 9:00am	The adhesion molecule NECTIN1 is a novel suppressor of metastasis in melanoma	Julien Ablain	
9:00am - 9:15am	Harnessing Sleeping Beauty transposon mutagenesis to model tumor heterogeneity in melanoma preclinical models	Ana Contreras-Sandoval	
9:15am - 9:30am	Cooperation in heterogeneous cell clusters accelerates melanoma metastasis	Nathaniel Campbell	
9:30am - 10:00am	<i>The Final Frontier: Tackling the Critical Challenges of Central Nervous System (CNS) Metastasis from Melanoma</i>	Michael Davies	
10:00am - 10:30am	Refreshment Break		Imperial Ballroom A&B
10:30am - 12:30pm	PLENARY SESSION 6 - Microenvironment	Session Chair: Ashani Weeraratna	Grand Ballroom B&C
10:30am - 11:00am	<i>Lymphatic Vessels and T cell Exit from Tumor Microenvironments</i>	Amanda Lund	
11:00am - 11:15am	Stromal and immune changes in the aged lung microenvironment create a permissive niche for the metastatic outgrowth of melanoma	Mitchell Fane	
11:15am - 11:30am	Uncovering microtubule-driven mechanisms of melanoma invasion	Samantha Stehbens	
11:30am - 11:45am	Targeting cancer-associated fibroblasts synergizes with anti-PD-1 immunotherapy in advanced acral melanoma	Yan Kong	
11:45am - 12:00pm	Melanoma-secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis	Kevin Kleffman	
12:00pm - 12:30pm	<i>dsRNA signalling as an inherent vulnerability in melanoma with implications in metastasis and response to immunomodulators</i>	Marisol Soengas	
12:30pm - 2:00pm	Lunch - Exhibit and Poster Viewing		Grand Ballroom Reception/ Imperial Ballroom Reception
12:45pm - 1:45pm	Emerging Trends and Challenging Cases in Melanoma Provided by Vindico Medical Education Supported by Bristol-Myers Squibb; Iovance Biotherapeutics; and Novartis Pharmaceuticals Corporation		Grand Ballroom B&C
2:00pm - 3:30pm	PLENARY SESSION 7 - Signaling Pathways and Targeted Therapies	Session Chair: Keiran Smalley	Grand Ballroom B&C
2:00pm - 2:30pm	<i>Immune-awakening is revealed by peripheral T cell evolution after a single cycle of immunotherapy</i>	Richard Marais	
2:30pm - 3:00pm	<i>Towards rational cancer and immune cell therapy combinations - a functional genomics approach</i>	Daniel Peeper	
3:00pm - 3:30pm	<i>Next generation strategies to overcome adaptive resistance to MAPK signaling-directed therapies.</i>	Poulikos Poulikakos	
3:30pm - 4:00pm	Refreshment Break		Imperial Ballroom A&B
4:00pm - 5:30pm	CONCURRENT BREAKOUT SESSION 8A - Metabolism	Session Chair: Ravi Amaravadi	Grand Ballroom B&C
4:00pm - 4:30pm	<i>Leveraging GTP Metabolism for the Suppression of Melanoma Invasion and Drug Resistance</i>	Mikhail Nikiforov	
4:30pm - 4:45pm	Metabolic reprogramming drives H3K4me3 remodeling in adaptive melanoma drug resistance through O-GlcNAc transferase	Helmut Schaidler	
4:45pm - 5:00pm	BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibition	Anna Han	
5:00pm - 5:30pm	<i>The metabolic regulation of melanoma metastasis</i>	Sean Morrison	
4:00pm - 5:30pm	CONCURRENT BREAKOUT SESSION 8B - Advances in Acral, Mucosal and Uveal Melanoma	Session Chair: Richard Carvajal	Grand Ballroom A&D
4:00pm - 4:30pm	<i>Single cell sequencing reveals new evolutionary complexity in uveal melanoma</i>	William Harbour	
4:30pm - 5:00pm	<i>The genomic landscape of acral melanoma</i>	Nicholas Hayward	
5:00pm - 5:15pm	Uncovering essential mediators of mutant GNAQ/11-driven oncogenesis in uveal melanoma	Jesse Riordan	
5:15pm - 5:30pm	Decreased antiviral type I IFN signaling in mucosal melanoma is associated with resistance to anti-PD-1 immunotherapy	Kasey Coutts	

Saturday, November 23rd	Functions	Speaker	Location
6:45am - 7:45am	Breakfast		Grand Ballroom Reception/ Imperial Ballroom Reception
6:45am - 12:00pm	Registration Open		Ballroom Foyer
7:15am - 7:45am	Updates on neoadjuvant therapy for melanoma	Jennifer Wargo	Grand Ballroom B&C
7:15am - 7:23pm	Introduction and INMC Overview	Georgina Long & Jennifer Wargo	
7:23pm - 7:35pm	Highlights on pathologic assessment and translational research	Richard Scoyler & Michael Tetzlaff	
7:35pm - 7:40pm	Regulatory overview and next steps	Liz Burton	
7:40pm - 7:45pm	Q&A	All Presenters	
8:00am-10:00am	PLENARY SESSION 9- Melanoma and the Immune System	Session Chair: Jennifer Wargo	Grand Ballroom B&C
8:00am - 8:30am	<i>The Biology of PD-1 Checkpoint Blockade</i>	Arlene Sharpe	
8:30am - 8:45am	Tumor-secreted MIDKINE drives immune checkpoint blockade resistance and defines poor patient prognosis	Daniela Cerezo Wallis	
8:45am - 9:00am	Multi-omic profiling demonstrates importance of B cells in immune checkpoint blockade response	Rohit Thakur	
9:00am - 9:15am	Innate immune cells play a role in induction of therapy resistance to anti-PD1 in Hu-mice melanoma model.	Rajasekharan Somasundaram	
9:30am - 9:45am	<i>Strength of interferon signaling and T cell infiltration in response to PD-1 blockade therapy</i>	Antoni Ribas	
10:00am - 10:30am	Refreshment Break		Ballroom Foyer
10:30am - 11:00am	A general model for oncogenic activation of ERK that informs treatment	Neal Rosen	Grand Ballroom B&C
11:00am - 12:50pm	PLENARY SESSION 10 - Late Breaking Clinical Abstracts	Session Chair: Martin McMahon	Grand Ballroom B&C
11:00am - 11:15am	Pharmacodynamic effect of tebentafusp (TCR-CD3 bispecific) on peripheral cytokines and association with OS in patients with advanced melanoma	Alexander Shoushtari	
11:15am - 11:30am	Retrospective analysis of patients with sentinel lymph node(SLN) positive melanoma(MEL) who received adjuvant anti-PD-1 therapy without completion lymph node dissection(CLND)	Zeynep Eroglu	
11:30am - 11:45am	Updated survival in patients (pts) with BRAF-mutant melanoma administered pembrolizumab (pembro), dabrafenib (D), and trametinib (T)	Pier Ferrucci	
11:45am - 12:00pm	Safety Data from a Single-Center Phase I/Ib Study of Concurrent Intravenous (IV) and Intrathecal (IT) Nivolumab (N) for Metastatic Melanoma (MM) Patients (pts) with Leptomeningeal Disease (LMD)	Isabella Glitza	
12:00pm - 12:15pm	5-Year Survival Update of Cobimetinib Plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Final Analysis of the coBRIM Study	Grant McArthur	
12:15pm - 12:30pm	Characteristics of Long-Term Survivors and Subgroup Analyses With Combination Nivolumab Plus Ipilimumab (NIVO+IPI) for Advanced Melanoma (CheckMate 067)	Georgina Long	
12:30pm - 12:50pm	Discussant	Kim Margolin	